BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 17625985)

  • 21. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study.
    Morice AH; Peterson S; Beckman O; Kukova Z
    Pulm Pharmacol Ther; 2008; 21(1):152-9. PubMed ID: 17376722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids.
    Kaiser H; Parasuraman B; Boggs R; Miller CJ; Leidy NK; O'Dowd L
    Ann Allergy Asthma Immunol; 2008 Sep; 101(3):295-303. PubMed ID: 18814453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once- vs twice-daily budesonide/formoterol in 6- to 15-year-old patients with stable asthma.
    Eid NS; Noonan MJ; Chipps B; Parasuraman B; Miller CJ; O'Brien CD
    Pediatrics; 2010 Sep; 126(3):e565-75. PubMed ID: 20713475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
    Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial.
    Zangrilli J; Mansfield LE; Uryniak T; O'Brien CD
    Ann Allergy Asthma Immunol; 2011 Sep; 107(3):258-65.e2. PubMed ID: 21875546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI.
    Murphy KR; Dhand R; Trudo F; Uryniak T; Aggarwal A; Eckerwall G
    Respir Med; 2015 Feb; 109(2):170-9. PubMed ID: 25596138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.
    Papi A; Paggiaro PL; Nicolini G; Vignola AM; Fabbri LM;
    Eur Respir J; 2007 Apr; 29(4):682-9. PubMed ID: 17107988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma.
    Jenkins C; Kolarikova R; Kuna P; Caillaud D; Sanchis J; Popp W; Pettersson E
    Respirology; 2006 May; 11(3):276-86. PubMed ID: 16635085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
    Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
    Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ; Houghton CM; Singh SD
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    LaForce C; Prenner BM; Andriano K; Lavecchia C; Yegen U
    J Asthma; 2005 Mar; 42(2):101-6. PubMed ID: 15871441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
    Palmqvist M; Arvidsson P; Beckman O; Peterson S; Lötvall J
    Pulm Pharmacol Ther; 2001; 14(1):29-34. PubMed ID: 11162416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma.
    Ställberg B; Ekström T; Neij F; Olsson P; Skoogh BE; Wennergren G; Löfdahl CG;
    Respir Med; 2008 Oct; 102(10):1360-70. PubMed ID: 18723335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.